{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:45:05Z","timestamp":1763747105335,"version":"3.38.0"},"reference-count":24,"publisher":"American Veterinary Medical Association (AVMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ajvr"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p><jats:bold>Objective<\/jats:bold>\u2014To retrospectively assess the safety and efficacy of recombinant human granulocyte colony-stimulating factor (G-CSF) used as part of autologous bone marrow transplantation in dogs with lymphoma.<\/jats:p>\n<jats:p><jats:bold>Animals<\/jats:bold>\u201421 dogs with lymphoma at any disease stage.<\/jats:p>\n<jats:p><jats:bold>Procedures<\/jats:bold>\u2014Medical records of dogs with lymphoma that underwent intensified chemotherapy and received an autologous bone marrow transplant following owner administration of recombinant human G-CSF (5 \u03bcg\/kg, SC, q 12 h) for 7 days between January 2007 and July 2009 were reviewed. Results of physical examinations and CBCs performed before and at intervals during a 24-month period after G-CSF treatment were assessed. The safety of recombinant human G-CSF administration was determined via assessment of both short-term (ie, during the 7-day G-CSF treatment period) and long-term adverse effects.<\/jats:p>\n<jats:p><jats:bold>Results<\/jats:bold>\u2014None of the dogs developed any adverse effect attributable to the administration of recombinant human G-CSF during G-CSF administration or during follow-up periods of 1 month to 2 years (median follow-up period, 4 months). Among the 18 dogs for which CBC results were available for analysis, mean circulating neutrophil count significantly increased after administration of recombinant human G-CSF, compared with value before treatment.<\/jats:p>\n<jats:p><jats:bold>Conclusions and Clinical Relevance<\/jats:bold>\u2014Results indicated that recombinant human G-CSF administered SC at a dosage of 5 \u03bcg\/kg every 12 hours for 7 days appeared to be safe and effective when used in dogs with lymphoma that were undergoing autologous bone marrow transplant.<\/jats:p>","DOI":"10.2460\/ajvr.73.6.894","type":"journal-article","created":{"date-parts":[[2012,5,23]],"date-time":"2012-05-23T20:02:35Z","timestamp":1337803355000},"page":"894-899","source":"Crossref","is-referenced-by-count":8,"title":["Use of recombinant human granulocyte colony-stimulating factor prior to autologous bone marrow transplantation in dogs with lymphoma"],"prefix":"10.2460","volume":"73","author":[{"given":"Amy E.","family":"Lane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa J. Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth M.","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1272","reference":[{"key":"ref1","series-title":"Cancer: principles and practice of oncology","first-page":"2619","article-title":"Leukopenia anemia and thrombocytopenia","author":"Kurkjian","year":"2008"},{"key":"ref2","series-title":"Semin Hematol","first-page":"95","article-title":"Bone marrow transplantation: a review","volume":"36","author":"Thomas","year":"1999"},{"issue":"suppl 1","key":"ref3","series-title":"Int J Hematol","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/BF03165291","article-title":"The international bone marrow transplant registry","volume":"76","author":"Goldman","year":"2002"},{"key":"ref4","series-title":"Bone Marrow Transplant","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/sj.bmt.1705616","article-title":"Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF?","volume":"39","author":"Cashen","year":"2007"},{"key":"ref5","series-title":"Int J Radiat Biol","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/09553009014550891","article-title":"Therapeutic use of recombinant human G-CSF (rhG-CSF) in a canine model of sublethal and lethal whole-body irradiation","volume":"57","author":"MacVittie","year":"1990"},{"key":"ref6","series-title":"J Vet Med Sci","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1292\/jvms.62.1205","article-title":"Effect of recombinant human granulocyte colony stimulating factor on lymphocyte blastogenesis in healthy dogs","volume":"62","author":"Hasegawa","year":"2000"},{"key":"ref7","series-title":"Vet Immunol Immunopathol","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.vetimm.2005.06.003","article-title":"In vitro effect of recombinant human granulocyte colony-stimulating factor on canine neutrophil apoptosis","volume":"108","author":"Oguma","year":"2005"},{"key":"ref8","series-title":"Chin Med J (Engl","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/00029330-200801020-00010","article-title":"Effects of granulocyte colony-stimulating factor on repair of injured canine arteries","volume":"121","author":"Mei","year":"2008"},{"key":"ref9","series-title":"J Am Anim Hosp Assoc","doi-asserted-by":"publisher","first-page":"236","DOI":"10.5326\/15473317-35-3-236","article-title":"Mitoxantrone and cyclophosphamide combination chemotherapy for the treatment of various canine malignancies","volume":"35","author":"Henry","year":"1999"},{"key":"ref10","series-title":"Blood","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1182\/blood.V72.4.1324.1324","article-title":"Correction of canine cyclic hematopoiesis with recombinant human granulocyte colony-stimulating factor","volume":"72","author":"Lothrop","year":"1988"},{"key":"ref11","series-title":"Exp Hematol","first-page":"1199","article-title":"Effects of recombinant granulocyte colony-stimulating factor treatment on hematopoietic cycles and cellular defects associated with canine cyclic hematopoiesis","volume":"18","author":"Pratt","year":"1990"},{"key":"ref12","series-title":"J Am Vet Med Assoc","first-page":"991","article-title":"Recombinant human granulocyte colony-stimulating factor for treatment of puppies with neutropenia secondary to canine parvovirus infection","volume":"213","author":"Rewerts","year":"1998"},{"key":"ref13","series-title":"Res Vet Sci","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/rvsc.2001.0464","article-title":"Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on leukocyte count and survival rate of dogs with parvoviral enteritis","volume":"70","author":"Mischke","year":"2001"},{"key":"ref14","series-title":"J Am Vet Med Assoc","first-page":"1957","article-title":"Effects of recombinant canine granulocyte colony-stimulating factor on white blood cell production in clinically normal and neutropenic dogs","volume":"200","author":"Mishu","year":"1992"},{"key":"ref15","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1939-1676.2006.tb02868.x","article-title":"A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma","volume":"20","author":"Frimberger","year":"2006"},{"key":"ref16","series-title":"Vet Comp Oncol","first-page":"195","volume":"2","year":"2004"},{"key":"ref17","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/j.1939-1676.2002.tb02411.x","article-title":"Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma","volume":"16","author":"Garrett","year":"2002"},{"key":"ref18","series-title":"Blood","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1182\/blood.V74.4.1308.bloodjournal7441308","article-title":"Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis of normal dogs and on hematopoietic recovery after otherwise lethal total body irradiation","volume":"74","author":"Schuening","year":"1989"},{"key":"ref19","series-title":"Bone Marrow Transplant","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/sj.bmt.1702641","article-title":"Pharmacokinetics and adverse events following 5-day repeated administration of lenograstim, a recombinant human granulocyte colony-stimulating factor, in healthy subjects","volume":"26","author":"Akizuki","year":"2000"},{"key":"ref20","series-title":"Bone Marrow Transplant","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/sj.bmt.1701977","article-title":"Administration of recombinant human granulocyte colony-stimulating factor to normal donors: results of the Spanish National Donor Registry. Spanish Group of Allo-PBT","volume":"24","author":"de la Rubia","year":"1999"},{"key":"ref21","series-title":"Blood","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1182\/blood-2007-07-097543","article-title":"Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges","volume":"111","author":"Anderlini","year":"2008"},{"key":"ref22","series-title":"Biol Blood Marrow Transplant","first-page":"45","article-title":"Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells","volume":"3","author":"Becker","year":"1997"},{"key":"ref23","series-title":"Ann Intern Med","doi-asserted-by":"publisher","first-page":"954","DOI":"10.7326\/0003-4819-118-12-199306150-00007","article-title":"Splenic extramedullary hematopoiesis in a patient receiving intermittently administered granulocyte colony-stimulating factor","volume":"118","author":"Litam","year":"1993"},{"key":"ref24","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(99)00268-8","article-title":"Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor","volume":"353","author":"Falzetti","year":"1999"}],"container-title":["American Journal of Veterinary Research"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/73\/6\/ajvr.73.6.894.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/ajvr\/73\/6\/ajvr.73.6.894.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/ajvr\/73\/6\/ajvr.73.6.894.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T12:31:06Z","timestamp":1741350666000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/73\/6\/ajvr.73.6.894.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":24,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.2460\/ajvr.73.6.894","relation":{},"ISSN":["0002-9645"],"issn-type":[{"type":"print","value":"0002-9645"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}